BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1455 related articles for article (PubMed ID: 12538684)

  • 41. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts.
    Hori J; Wang M; Miyashita M; Tanemoto K; Takahashi H; Takemori T; Okumura K; Yagita H; Azuma M
    J Immunol; 2006 Nov; 177(9):5928-35. PubMed ID: 17056517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of B7-H1 in inflammatory renal tubular epithelial cells.
    Chen Y; Zhang J; Li J; Zou L; Zhao T; Tang Y; Wu Y
    Nephron Exp Nephrol; 2006; 102(3-4):e81-92. PubMed ID: 16282703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands.
    Karasar P; Esendagli G
    Breast Cancer Res Treat; 2014 Jun; 145(3):605-14. PubMed ID: 24816762
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
    Freeman GJ; Long AJ; Iwai Y; Bourque K; Chernova T; Nishimura H; Fitz LJ; Malenkovich N; Okazaki T; Byrne MC; Horton HF; Fouser L; Carter L; Ling V; Bowman MR; Carreno BM; Collins M; Wood CR; Honjo T
    J Exp Med; 2000 Oct; 192(7):1027-34. PubMed ID: 11015443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice.
    Gotsman I; Grabie N; Dacosta R; Sukhova G; Sharpe A; Lichtman AH
    J Clin Invest; 2007 Oct; 117(10):2974-82. PubMed ID: 17853943
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.
    Fife BT; Pauken KE; Eagar TN; Obu T; Wu J; Tang Q; Azuma M; Krummel MF; Bluestone JA
    Nat Immunol; 2009 Nov; 10(11):1185-92. PubMed ID: 19783989
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
    Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
    Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of programmed death 1 and its ligands in the liver of autoimmune hepatitis C57BL/6 mice.
    Cao J; Liu FX; Yu MX
    Chin Med J (Engl); 2009 Aug; 122(16):1941-6. PubMed ID: 19781375
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation.
    Yang W; Li H; Chen PW; Alizadeh H; He Y; Hogan RN; Niederkorn JY
    Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):273-80. PubMed ID: 18791172
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo.
    Habicht A; Kewalaramani R; Vu MD; Demirci G; Blazar BR; Sayegh MH; Li XC
    Am J Transplant; 2007 Dec; 7(12):2683-92. PubMed ID: 17924994
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis.
    Rodig N; Ryan T; Allen JA; Pang H; Grabie N; Chernova T; Greenfield EA; Liang SC; Sharpe AH; Lichtman AH; Freeman GJ
    Eur J Immunol; 2003 Nov; 33(11):3117-26. PubMed ID: 14579280
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Immuno-histological and-cytological examinations on distribution of newly reported co-stimulatory molecules in germinal center of human tonsils].
    Sugita G; Fujimori M; Ikeda K
    Nihon Jibiinkoka Gakkai Kaiho; 2005 Jan; 108(1):31-7. PubMed ID: 15712495
    [TBL] [Abstract][Full Text] [Related]  

  • 54. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells.
    Hobo W; Maas F; Adisty N; de Witte T; Schaap N; van der Voort R; Dolstra H
    Blood; 2010 Nov; 116(22):4501-11. PubMed ID: 20682852
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions.
    Porichis F; Hart MG; Zupkosky J; Barblu L; Kwon DS; McMullen A; Brennan T; Ahmed R; Freeman GJ; Kavanagh DG; Kaufmann DE
    J Virol; 2014 Mar; 88(5):2508-18. PubMed ID: 24352453
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.
    Keir ME; Latchman YE; Freeman GJ; Sharpe AH
    J Immunol; 2005 Dec; 175(11):7372-9. PubMed ID: 16301644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.
    Latchman YE; Liang SC; Wu Y; Chernova T; Sobel RA; Klemm M; Kuchroo VK; Freeman GJ; Sharpe AH
    Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10691-6. PubMed ID: 15249675
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation.
    Currie AJ; Prosser A; McDonnell A; Cleaver AL; Robinson BW; Freeman GJ; van der Most RG
    J Immunol; 2009 Dec; 183(12):7898-908. PubMed ID: 20007574
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.
    Ghiotto M; Gauthier L; Serriari N; Pastor S; Truneh A; Nunès JA; Olive D
    Int Immunol; 2010 Aug; 22(8):651-60. PubMed ID: 20587542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.
    Blazar BR; Carreno BM; Panoskaltsis-Mortari A; Carter L; Iwai Y; Yagita H; Nishimura H; Taylor PA
    J Immunol; 2003 Aug; 171(3):1272-7. PubMed ID: 12874215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 73.